The group's principal activity is to develop, produce and market pharmaceutical delivery solutions. Pharmaceutical delivery solutions includes needle-free and mini-needle injector systems, gel technologies and transdermal products. The group distributes its needle-free injector systems for the delivery of insulin and growth hormone in more than 20 countries. The group has several products and compound formulations under development and is conducting ongoing research to create new products and formulations that combine various elements of the company's technology portfolio. The group's major customers include ferring pharmaceutical nv and biosante pharmaceuticals, inc.
